InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,473.23
(
0.00%
)
US TECH 100
19,408.40
(
0.03%
)
Dow Jones
38,778.10
(
0.00%
)
Brent Oil
83.75
(
-0.18%
)
Bitcoin
65,224.96
(
-1.90%
)
Post# of 252235
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

genisi

Send PM Follow Ignore
Followers 29
Posts 5148
Boards Moderated 0
Alias Born 05/24/2006

genisi

Re: dewophile post# 153397

Saturday, 12/01/2012 5:14:34 PM

Saturday, December 01, 2012 5:14:34 PM

Post# of 252235

GS-5885, as far as i can tell, is not active in genotypes 2 and 3

Indeed it is less potent against GT2/3 in replicon assays I've seen (don't recall clinical data), but data from phase II of sofosbuvir/daclatasvir regimen were quite good in GT2/3:

http://mobile.ilcapp.eu/EASL_161/poster_24858/program.aspx

So, I think it's quite possible that GILD's NS5A GS-5885 can produce similar results.

Edit: just kept reading and seen the following posts on the issue but I'll leave mine just because it has the link to the EASL poster...
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up